Comparing the current results to its competitors, Prosomnus Inc reported Revenue increase in the 2 quarter 2024 by 34.44 % year on year. The sales growth was above Prosomnus Inc 's competitors' average revenue growth of 6.27 %, achieved in the same quarter.
Prosomnus Inc 's Comment on Competition and Industry Peers
The company operates in the obstructive sleep apnea (OSA) treatment market with its ProSomnus precision intraoral devices, which feature patented technology, Medical Grade Class VI materials, and a proprietary iterative titration system. Its digital prescription and manufacturing process aims to provide cost-effective production relative to competitors. ProSomnus devices differ from CPAP, HNS, and other therapies by not requiring invasive surgeries or ongoing consumable expenses. These devices are reimbursable by multiple major commercial medical payors, including United Healthcare, which has updated its medical policy to include oral appliance therapy such as ProSomnus's products. The company competes with manufacturers of surgically implanted upper airway stimulation devices, notably Inspire Medical (Inspire). Some competitors possess greater financial resources or more diversified product lines and markets, potentially allowing faster adaptation to market changes and innovations. The company safeguards its intellectual property through patents, copyrights, trademarks, trade secrets, and confidentiality agreements, holding nine issued U.S. utility patents as of March 25, 2023. There is no active patent litigation involving the company.
January 29, 2024
In a startling turn of events, Philips Respironics, a leading manufacturer of obstructive sleep apnea (OSA) devices, recently announced the recall and discontinuation of a significant number of its products due to health concerns. As the sleep apnea community reels from this unexpected setback, there is a pressing need for alternative solutions to ensure uninterrupted support for affected patients. Fortunately, ProSomnus, a pioneering company in the field of sleep medicine, is stepping forward to bridge this gap and provide much-needed relief to those suffering from sleep apnea.The recall by Philips Respironics comes as a blow to the millions of individuals worldwide who rely on their OSA devices to manage t...
In a recent press release, ProSomnus Inc announced groundbreaking data published by the Cureus Journal of Medical Science that demonstrates the successful treatment of obstructive sleep apnea (OSA) using their precision oral appliance devices. The findings suggest that patients using ProSomnus devices experienced a significant decrease in apnea-hypopnea index (AHI) events per hour, while also exhibiting strong treatment adherence. When compared to its competitors, ProSomnus Inc reported stable revenue growth in the third quarter of 2023. This article explores the implications of ProSomnus Precision Oral Appliance Devices in revolutionizing the treatment of OSA. Decreased Apnea-Hypopnea Index Ev...
Axonics Inc is a medical technology company that focuses on the development and commercialization of solutions for treating bladder and bowel dysfunction. Their business model revolves around the manufacturing and sales of implantable neuromodulation devices that help patients suffering from these conditions. They aim to provide innovative and effective solutions that enhance patients' quality of life while maintaining partnerships with healthcare professionals and expanding their market reach.
Pro dex Inc is a company that operates using a direct sales business model, selling their products directly to customers without the need for intermediaries. Their revenue is generated through the sales of their medical device components, primarily to original equipment manufacturers (OEMs) in the medical and dental industries. Pro dex Inc focuses on providing high-quality products and establishing long-term relationships with their customers to drive growth and profitability.
Penumbra Inc operates on a business model that focuses on the development and manufacturing of innovative medical devices. They aim to provide cutting-edge technologies and solutions to improve patient outcomes in various medical fields. The company primarily generates revenue through the sales of their medical devices to healthcare professionals and institutions worldwide.
ResMed Inc is a medical equipment company focused on creating and manufacturing products for the treatment of sleep apnea and other respiratory conditions. Their business model includes a combination of direct sales and partnerships with healthcare providers, ensuring wide distribution of their devices to patients worldwide. By leveraging advanced technology and data-driven solutions, ResMed aims to enhance patient care and improve health outcomes for individuals with sleep-related breathing issues.
Stryker Corps business model focuses on innovation in medical technologies and devices, specializing in areas such as orthopedics, surgical equipment, and neurotechnology, to enhance patient care and improve outcomes in the healthcare industry.
Sources:
Prosomnus Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prosomnus Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
